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Mitochondrial DNA (mtDNA) depletion and deletion syndrome encompasses a group of
disorders caused by mutations in genes involved in mtDNA replication and maintenance.
The clinical phenotype ranges from fatal infantile hepatocerebral forms to mild adult
onset progressive external ophthalmoplegia (PEO). We report the case of a patient
with PEO and multiple mtDNA deletions, with two new homozygous mutations in
RNASEH1. The first mutation (c.487T>C) is located in the same catalytic domain as
the four previously reported mutations, and the second (c.258_260del) is located in
the connection domain, where no mutations have been reported. In silico study of
the mutations predicted only the first mutation as pathogenic, but functional studies
showed that both mutations cause loss of ribonuclease H1 activity. mtDNA replication
dysfunction was demonstrated in patient fibroblasts, which were unable to recover
normal mtDNA copy number after ethidium bromide-induced mtDNA depletion. Our
results demonstrate the pathogenicity of two new RNASEH1 variants found in a patient
with PEO syndrome, multiple deletions, and mild mitochondrial myopathy.
Keywords: mtDNA, mitochondrial disease, PEO, multiple mtDNA deletions, RNASEH1
INTRODUCTION
The mitochondrion is a cellular organelle crucial for cell metabolism that integrates various
metabolic pathways, including oxidative phosphorylation (OXPHOS), fatty acid oxidation, Krebs
cycle, urea cycle, gluconeogenesis, and ketogenesis (Gorman et al., 2016). Mitochondrial function
is under the control of two genomes, nuclear DNA (nDNA) and mitochondrial DNA (mtDNA).
mtDNA is a 16.6-kb circular and double-stranded DNA molecule that encodes 2 rRNAs, 22 tRNAs,
and 13 peptides from OXPHOS complexes I, III, IV, and V. However, most mitochondrial proteins
are encoded by nDNA genes (Anderson et al., 1981). Nuclear-encoded mitochondrial proteins
are synthetized in the cytosol and transported into the mitochondria where they perform their
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functions (Herrmann et al., 2012). A large number of these
mitochondrial proteins are OXPHOS complex subunits or
complex assembly factors and therefore, they are directly
involved in the electron transport chain and energy production
in the form of ATP. Furthermore, a group of nuclear genes are
involved in several mitochondrial processes, such as mtDNA
maintenance, transcription and translation, and control of
mitochondrial dynamics, which are also essential for proper
OXPHOS function. When a malfunction occurs in one of
these proteins, the mitochondrial OXPHOS system is unable
to produce sufficient energy to maintain cell requirements,
and this deficit leads to a number of mitochondrial diseases
(Wallace, 1999). Therefore, mitochondrial diseases are caused by
mutations in mtDNA genes and in a very long list of nuclear
mitochondrial-related genes (Cerritelli et al., 2003; Ruhanen
et al., 2011; Uhler and Falkenberg, 2015).
Multiple mtDNA genome copies are present in cells to provide
the components for energy production. mtDNA replication is
unsynchronized with the cell cycle as it occurs in dividing
and postmitotic cells. Correct mtDNA maintenance requires
adequate expression of a number of nuclear-encoded proteins
involved in mtDNA replication, mitochondrial deoxynucleotide
pool synthesis, mitochondrial dynamics, and other proteins
with uncertain function. Changes in these genes are associated
with secondary mtDNA changes, such as mtDNA deletions
or depletion, which cause OXPHOS dysfunction and result in
a group of disorders known as mitochondrial depletion and
deletion syndromes (MDDSs). The clinical phenotype associated
with MDDSs ranges from fatal infantile hepatocerebral forms
to mild adult-onset syndromes, such as progressive external
ophthalmoplegia (PEO) (Suomalainen and Kaukonen, 2001;
El-Hattab et al., 2017).
The human RNASEH1 gene encodes an endonuclease
involved in DNA replication in both the nucleus and
mitochondria. Ribonuclease H1 (RNase H1) is the only
known ribonuclease of this type in the mitochondria
(Al-Behadili et al., 2018; Rusecka et al., 2018) and, in particular,
this enzyme is implicated in the RNA degradation of the
double-stranded RNA-DNA hybrid created to prime DNA
synthesis during mtDNA replication (Cerritelli et al., 2003;
Ruhanen et al., 2011; Uhler and Falkenberg, 2015; Al-Behadili
et al., 2018). RNASEH1 mutations have been described in
patients with clinical MDDS associated with adult-onset PEO
and multiple mtDNA deletions (Reyes et al., 2015; Bugiardini
et al., 2017; Sachdev et al., 2018). The predominant clinical
traits of patients with RNASEH1 mutations are PEO, ptosis,
dysphagia, facial and/or proximal weakness, ataxia, and
respiratory impairment.
To date, only four mutations in RNASEH1, all occurring in
the catalytic RNase H1 domain, have been identified in a total
of 14 patients with a mild clinical phenotype (Reyes et al., 2015;
Bugiardini et al., 2017; Sachdev et al., 2018). Here, we report the
case of a patient diagnosed with mild mitochondrial myopathy
characterized by PEO and multiple mtDNA deletions caused by
two previously unreported mutations in the RNASEH1 gene, one
located in the catalytic domain and the other in the RNase H1
connection domain.
MATERIALS AND METHODS
All the experimental protocols were performed with
appropriate informed consent and approval of the Clinical
Research Ethics Committee of the Hospital Universitari Vall
d’Hebron (PR(IR)66/2016).
Histopathological Studies
A skeletal muscle biopsy from the left biceps was performed.
Five-micron sections of frozen muscle were double-stained
with cytochrome c oxidase (COX) and succinate dehydrogenase
(SDH) (Dubowitz and Sewry, 2007).
Cell Culture Conditions
Patient fibroblasts and fibroblasts from healthy age-matched
donors were obtained by skin biopsy and used in the study.
Fibroblasts were grown in high glucose (4.5 g/L) DMEM
(Gibco) supplemented with 10% FBS, 200 mM L-glutamine,
100 mM sodium pyruvate 100 U/mL penicillin and 0.1 mg/mL
streptomycin. In order to force OXPHOS for ATP production, in
some experiments cells were grown in DMEM without glucose
(Gibco) supplemented with 10% FBS, 1 g/L galactose, 200 mM
L-glutamine, 100 mM sodium pyruvate, 100 U/mL penicillin and
0.1 mg/mL streptomycin.
To induce mtDNA depletion in fibroblasts, the same number
of cells was seeded and cultured to confluence (day 0). Fibroblasts
were then treated with 15 ng/mL ethidium bromide (EtBr) for
4 days. After EtBr was withdrawn (day 4), cells were kept in
culture media for 10 additional days (day 14). Cells were collected
on days 0, 2, 4, 7, 9, and 14, and maintained frozen at−20◦C until
further DNA extraction.
Genetic Studies
We sequenced the exonic and intron flanking regions of
17 nuclear genes (DGUOK, DNA2, FBXL4, MGME1, MFN2,
MPV17, OPA1, POLG, POLG2, RNASEH1, RRM2B, SLC25A4,
SUCLA2, SUCLG1, SPG7, TK2, and TWNK) involved in mtDNA
replication and maintenance by next-generation sequencing,
using a previously designed panel with GeneRead Custom Panel
V.2 (Qiagen) technology. Libraries were prepared with the
NEBNext Ultra II DNA Library Prep Kit for Illumina (New
England Biolabs), sequenced on the MiSeq platform (Illumina)
and analyzed with GeneRead Targeted Enrichment Exon Panel
Data Analysis (Qiagen) software. The mutations identified were
verified by conventional Sanger sequencing.
Quantification of mtDNA Copy Number
and Analysis of Multiple Deletions
Total DNA was isolated from fibroblast pellets or muscle biopsies
with the QIAamp DNA Mini kit (Qiagen). The mtDNA copy
number was quantified by real-time PCR in the ABI PRISM 7500
Sequence Detection System (Applied Biosystems). mtDNA was
detected using a custom-designed TaqMan probe and primers for
the 12S rRNA gene (Andreu et al., 2009), and nuclear DNA using
the TaqMan RNase P Control Reagent kit (ThermoFisher) in a
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multiplex reaction with the TaqMan Universal PCR Master Mix
with UNG (Applied Biosystems).
The presence of multiple mtDNA deletions was analyzed by
long-range PCR (LPCR) (Nishigaki et al., 2004).
Western Blot
Western blot was used to analyze the protein extracts obtained
from the fibroblast mitochondria-enriched fractions using
the Mitochondria Isolation Kit for Cultured Cells (Abcam)
following the manufacturer’s instructions. Mitochondrial pellets
were resuspended in the resuspension reagent provided by
the supplier, supplemented with a protease inhibitor cocktail
(cOmplete EDTA-free, Roche). Samples were heat-denatured in
loading buffer (60 mM Tris–HCl pH6.8, 20% glycerol, 20% SDS,
5% β- mercaptoethanol, 0.05% bromophenol blue) and separated
by 12% SDS-PAGE. Proteins were transferred to Immun-
Blot PVDF membranes (Bio-Rad) and detected using primary
mouse monoclonal antibodies against human RNase H1 protein
(ab56560, Abcam) and rabbit polyclonal antibodies against
succinate dehydrogenase (SDHA; NB-22-14256, Neo Biotech).
Recombinant Human RNase H1 Protein
Production
We produced 4 different plasmids containing the following
RNASEH1 cDNA sequences: single mutant c.487T>C
[p.(Tyr163His)], single mutant c.258_260del [p.(Gln86del)],
double mutant c.487T>C/c.258_260del [p.(Tyr163His)/
p.(Gln86del)] and wild-type (WT). We obtained the various
RNase H1 proteins as previously described (Cerritelli and
Crouch, 1998). Briefly, total RNA was extracted from patient
and control fibroblasts using the RNeasy Mini kit (Qiagen).
The double mutant and WT RNASEH1 cDNAs were generated
using the High-capacity cDNA Reverse Transcription kit
(Applied Biosystems), amplified by specific PCR using the
Expand High Fidelity PCR System (Roche) with a specific pair
of primers (forward 5′-ATGTTCTATGCCGTGAGGAG-3′
and reverse 5′-TCAGTCTTCCGATTGTTTAGC-3′) and
cloned into the pCR 2.1 TOPO TA vector (Invitrogen).
The single mutant cDNAs were obtained by site-directed
mutagenesis of the WT cDNA using the Q5 Site-Directed
Mutagenesis kit (New England Biolabs). Two pairs of
primers were used to introduce the c.487T>C point mutation
(forward 5′-AATCGGCGTTCACTGGGGGCCA-3′ and reverse
5′-CCTGCTCGCGGCCTTCTACGC-3′) and the c.258_260del
deletion (forward 5′-TGGACAAGAATCGGAGGCGAAA-3′
and reverse 5′-TGATTTTCATGC CCTTCTGAAACTTCC-3′).
We confirmed the absence of non-specific mutations by direct
Sanger sequencing.
Each RNASEH1 cDNA (WT, double mutant, mutant
c.487T>C, and mutant c.258_260del) was subcloned into
the pET-15b expression vector (Novagen) and transformed
into Escherichia coli One Shot BL21(DE3) pLysS chemically
competent cells (Invitrogen). Recombinant protein synthesis was
induced in the bacterial cell culture with 1 mM IPTG, collected
after cell lysis and purified using the Ni-NTA Fast Start Kit
(Qiagen) based on histidine tag affinity columns.
RNase H1 Activity Assay
The RNase H1 activity assay is based on the capability of
recombinant protein to degrade RNA using a radiolabeled
RNA-DNA heteroduplex as substrate (Wu et al., 2001; Alla
and Nicholson, 2012). For heteroduplex generation, we labeled
the 5′-end RNA oligo with 32P using [ϒ−32P]ATP. The
labeling reaction was performed by incubating 200 pmol RNA
oligonucleotide (5′-GAAAUACGGUCCGAAACGUUG-3′) with
3 pmol [ϒ−32P]ATP (3000 Ci/mmol), 290 pmol ATP, and
10 units of T4 polynucleotide kinase in 25 µl of T4 buffer
(10 mM MgCl2, 5 mM DTT and 70 mM Tris–HCl, pH 7)
for 1 h at 37◦C. The 32P-labeled RNA oligonucleotide was
then purified with Quick Spin Columns for Radiolabeled RNA
Purification (Roche). For RNA/DNA heteroduplex annealing,
1 µM 32P-labeled RNA was incubated with 100 µM DNA
oligonucleotide (5′-CAACGTTTCGGACCGTATTTC-3′), 0.5 M
KCl, 250 mM HEPES, and 0.1M EDTA at 90◦C for 5 min, slowly
cooled-down to 37◦C and then placed on ice.
The enzyme activity assay was performed by incubating
250 nM 32P-labeled DNA/RNA hybrid with 40 nM of
recombinant RNase H1 protein and reaction buffer (0.5 M
KCl, 500 nM DTT, 250 nM HEPES and 500 µM MgCl2)
for 1 h at 30◦C. The reaction was stopped by adding an
equal volume of stopping solution [95% (v/v) formamide, and
20 mM EDTA]. Samples were heated at 90◦C for 2 min and
then resolved on 15% polyacrylamide gel with 7 M urea and
TBE buffer. The gel was dried and the labeled bands were
visualized by autoradiography.
Statistics and Quantification
Data were analyzed using the GraphPad PRISM software
(GraphPad software) and are presented as the mean ± SD.
The protein and radiolabeled RNA bands were quantified by
densitometry using ImageJ software (NIH).
RESULTS
Case Report
A 53-year-old patient was consulted for progressive palpebral
ptosis without diplopia of 2 years duration, associated with
a feeling of early fatigue with exercise, mild dysphagia and
dysarthria. Physical examination showed moderate, fatigue-
unrelated palpebral ptosis, associated with limitations in bilateral
ocular movement. No significant muscle weakness was observed,
except for a slight lingual weakness. The patient had slightly
elevated serum creatine kinase concentration (<500 U/L).
Examination of biceps muscle biopsy showed some ragged
red fibers and abundant COX-negative fibers, consistent with
mitochondrial myopathy (Figure 1A). No fiber size variability or
central nuclei were seen. LPCR of DNA extracted from muscle
biopsy revealed multiple deletions (Figure 1B) suggestive of
mtDNA instability syndrome, and real-time PCR showed normal
mtDNA copy number (Figure 1C).
Three years after the first visit there was little disease
progression, with the exception of respiratory muscle weakness
requiring non-invasive nocturnal ventilation.
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FIGURE 1 | Histological and molecular findings in muscle biopsy specimens. (A) COX/SDH double staining of the patient’s muscle biopsy. The yellow scale bar
represents 200 µm. Arrows show COX-negative fibers. (B) LPCR performed in DNA from the patient (P) and control (C) muscle samples. After electrophoresis,
mtDNA deletions are seen as multiple bands in the agarose gel. (C) mtDNA copy number measured by qRT-PCR in skeletal muscle samples from patient (P) and
controls (C1, C2, C3, and C4). Results are expressed as the ratio between the 12S mtDNA gene and the RNase P nuclear gene. Bars represent the mean
(+SD, n = 3).
Genetic and Molecular Studies
DNA sequencing from muscle biopsy specimens with the
custom panel V2 (Qiagen) disclosed 2 potentially pathogenic
variants in homozygosis in the RNASEH1 gene: c.258_260del,
a three-nucleotide in-frame deletion in exon 3 causing a
glutamine residue deletion [p.(Gln86del)], and c.487T>C,
a single nucleotide change in exon 4 causing a missense
mutation [p.(Tyr163His)] (NM_002936.3, NP_002927.2)
(Figures 2A,B).
First, we analyzed the population frequency of the variants,
and found that both were extremely rare; c.258_260del was
found in only 35 of 276096 alleles (0.013%), none in
homozygosis in the gnomAD database, and the c.487T>C
variant had not been previously reported in the databases
consulted. To study the implication of these mutations in
the patient’s phenotype, we performed an amino acid residue
conservation study and in silico prediction of pathogenicity.
The conservation studies showed that the glutamine residue
at position 86 in RNase H1 protein is only conserved in
primates, whereas the tyrosine residue at position 163 and
the surrounding region was conserved in all species analyzed
(Figure 2B). The in silico pathogenicity studies performed
with on-line open tools classified the c.487T>C variant as
“probably damaging” by Polyphen (score 1), “damaging” by
SIFT (score 0) and “disease causing” by Mutation Taster. For
the c.258_260del, Mutation Taster classified the variant as a
polymorphism and the Alamut splicing predictor did not detect
an alternative splicing, although it classified the variant as of
“unknown pathogenicity.” No results were obtained with the
other tools, as these predictors are unable to classify small
deletions or insertions.
We measured RNase H1 enzyme activity with an in vitro
assay using a DNA/RNA hybrid oligonucleotide as substrate
and the wild-type or mutated recombinant proteins containing
each single mutation or a combination of both. Only the wild-
type recombinant protein displayed RNase H1 activity. No
residual activity was detected for any mutated recombinant
protein (Figure 2C).
Characterization of the Mutation in Skin
Fibroblasts
RNase H1 steady state levels were measured in skin fibroblast
mitochondrial protein extracts from the patient and a controls.
Western blot analysis showed a marked RNase H1 reduction in
the patient’s sample: residual protein level was only 49% of the
mean levels in control fibroblasts (Figure 3A).
We compared the capacity for growth of patient fibroblasts
and two control cell lines. Cells were cultured in medium with
glucose for 12 days with regular medium changes, and cell
counts were performed at several time points. No differences in
growth were observed between the patient and control cell lines
(Figure 3B). In order to force cells to preferentially use oxidative
phosphorylation for ATP production, we grew cells in culture
medium supplemented with galactose instead of glucose, and
observed an expected growth rate reduction in all cell lines, with
no differences between control and patient cells (Figure 3B).
Mitochondrial DNA content and integrity was analyzed in
patient fibroblasts, but neither deletions nor mtDNA depletion
were detected. As the fibroblasts did not show a spontaneous
mtDNA phenotype, we induced mtDNA depletion in samples
from the patient and two controls. To this end, we treated
fibroblasts with EtBr and then assessed their ability to recover
normal mtDNA copy number. mtDNA copy number had
decreased at 2 and 4 days after EtBr treatment in all fibroblast
lines (Figure 3C). At 5 days after EtBr removal, control fibroblasts
had recovered the initial mtDNA copy number, which continued
to increase up to the end of the experiment (10 days), whereas
patient fibroblasts were unable to recuperate, showing mtDNA
copy number at only 60% (Figure 3C).
DISCUSSION
Mitochondrial depletion and deletion syndromes are a group of
mitochondrial disorders caused by mutations in nuclear genes
associated with mtDNA instability. These conditions have a wide
variety of clinical presentations ranging from a spectrum of
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FIGURE 2 | Genetic and enzymatic study. (A) Summary of the known
RNASEH1 mutations. Location of the mutations in RNASEH1 and their
distribution along the four different RNase H1 protein domains are indicated
with dashed lines (M, mitochondrial targeting sequence; HBD, hybrid binding
domain; CD, connection domain; H-Domain, catalytic domain). The two new
variants are boxed within the highlighted squares. (B) Amino acid
conservation study. CLUSTAL online software amino acid alignment of the
RNase H1 regions containing the new variants. The patient’s mutated residues
are shadowed and the conserved residues are indicated with an asterisk.
(C) Enzyme activity of the wild type (WT), double mutated
(p.Tyr163His/p.Gln86del), p.Tyr163His, and p.Gln86del recombinant RNase
H1 proteins. The ssOligo corresponds to the uncut RNA chain of the
DNA:RNA heteroduplex, whereas the ss processed Oligo is the digested RNA
oligomer.
severe early onset neurologic or other organ-specific syndromes
to adult-onset milder encephalomyopathies characterized by
PEO (Viscomi and Zeviani, 2017). One possible genetic cause
of the milder clinical form is the presence of mutations in
RNASEH1, an uncommon occurrence with only 14 patients
reported to date, all of them showing PEO as a clinical trait
(Reyes et al., 2015; Bugiardini et al., 2017). Here, we report
the case of a patient with PEO and additional clinical features
commonly reported in other patients with RNASEH1 mutations,
such as dysphagia, dysarthria, respiratory impairment, and slight
lingual muscle weakness (Bugiardini et al., 2017). Histological
and molecular studies in skeletal muscle found ragged red fibers,
COX-defective fibers, and multiple mtDNA deletions, which are
always present in patients with RNASEH1 mutations. Although
the clinical features of our patient matched many of those
reported in others with RNASEH1 mutations, the low prevalence
of the disease and the large number of genes associated with these
symptoms hampered the diagnosis.
Our patient showed two mutations in RNASEH1, detected
by high-throughput sequencing using a custom panel of
genes involved in mtDNA replication and maintenance. High-
throughput sequencing techniques have improved the diagnosis
of mitochondrial diseases. In fact, all reported RNASEH1
mutations have been detected using target or whole-exome
sequencing (Reyes et al., 2015; Bugiardini et al., 2017). The
panel used in this study provided a fast and cost-effective way
to establish the genetic diagnosis in a patient with a specific
MDDS. However, the number of genes known to be involved
in these phenotypes is growing, and next-generation sequencing
techniques, such as whole exome sequencing, are sometimes
needed to reach a definite genetic diagnosis.
Maturation of mtDNA during replication involves RNase H1
and at least two additional proteins encoded by the MGME1
and DNA2 genes, which are also implicated in MDDSs with
PEO (Kornblum et al., 2013; Ronchi et al., 2013; Viscomi and
Zeviani, 2017). RNase H1 protein is essential for terminating
replication by removing the replication primer, and defects in its
function cause deceleration and stalling of mtDNA replication
(Reyes et al., 2015). Here, we investigated the molecular effects
of RNASEH1 mutations on the patient’s fibroblasts and found
a marked decrease in RNase H1 protein in mitochondria,
indicating that one or both variants affected protein stability.
However, we did not observe multiple deletions or mtDNA
depletion, which likely explains the normal growing rate seen
in the OXPHOS-obligatory culture conditions. This limitation
of the model, commonly observed in cultured fibroblasts from
other MDDSs, is usually bypassed by assessing the ability to
restore normal mtDNA copy number following induced mtDNA
depletion (Stewart et al., 2011; Kornblum et al., 2013; Dalla Rosa
et al., 2016). In our case, fibroblast mtDNA recovery was clearly
reduced, thus demonstrating that the pathogenesis of the disease
was related to an mtDNA replication defect, in agreement with
other cases involving RNASEH1 mutations (Holmes et al., 2015;
Reyes et al., 2015).
The RNASEH1 mutations found were homozygous and
neither had been previously described as disease-related.
Genetic study of the mutations in the patient’s parents was
not possible, but we know that they were consanguineous,
which reduces the possibility of apparent homozygosity due
to compound heterozygosity of the two mutations with an
overlapping long-range gene deletion (Landsverk et al., 2012;
Martins Rda et al., 2014; Shibata et al., 2015). We also knew that
neither of the patient’s parents were affected, which concurs with
the previously reported autosomal recessive inheritance of the
disease (Reyes et al., 2015; Bugiardini et al., 2017).
In vitro study of recombinant protein function carrying
the two mutations demonstrated a complete loss of activity,
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FIGURE 3 | Functional studies in patient fibroblasts. (A) Western blot analysis of RNase H1 in mitochondria-enriched protein extracts from patient (P) and control
(C1, C2, and C3) fibroblasts. The bar chart represents relative quantification of RNase H1 protein by densitometry. Results are expressed as the percentage of the
mean (+SD, n = 3) RNase H1 protein density value obtained with control fibroblasts corrected with the SDHA protein load control. (B) Cell growth curves of
fibroblasts incubated at 37◦C in culture media supplemented with glucose (4.5 g/L) or galactose (1 g/L) during 12 days. The black lines correspond to control
fibroblasts and the gray line to patient fibroblasts. Results are expressed as the mean fold increase with respect to the total cell count at time 0 (±SD, n = 3).
(C) Recovery from mtDNA depletion in fibroblasts. Control (black lines) and patient (gray line) fibroblasts were incubated at 37◦C in complete culture media
supplemented with EtBr (15 ng/mL) during 4 days. EtBr was removed from culture media (dashed vertical line) and cells were maintained in culture during 10
additional days. DNA was extracted on days 0, 2, 4, 7, 9, and 14, and mtDNA copy number was quantified by qRT-PCR as the ratio between the 12S and RNase P
gene copy numbers. Results are expressed as the mean mtDNA copy number referred to day 0, for each cell line (±SD, n = 2).
which points to them as the cause of the disease. Our
functional studies also showed that each mutation separately
resulted in complete loss of RNase H1 activity, suggesting
that either mutation alone can cause the disease. These results
were partially consistent with our conservation study and our
in silico prediction of pathogenesis, since all results indicated
that the missense mutation located in the catalytic domain was
pathogenic. However, pathogenicity prediction of the deletion
located in the connection domain did not concur with the results
obtained from the functional study. One potential explanation
is that the deletion was predicted to be a polymorphism or of
unknown pathogenicity because it was found in the population
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in heterozygosis at a frequency of 0.01% (gnomAD database).
Moreover, only two of the four predictors used were suitable
for assessing small deletions and their predictions are based,
among other factors, on the mutation frequency in population
databases, evolutionary conservation, splice-site changes, and
loss of protein features (Schwarz et al., 2014), thus highlighting
the importance of using various pathogenic predictors and
functional validation to study new variants. Finally, both variants
can be classified as “likely pathogenic” following the American
College of Medical Genetics and Genomics (ACMG) guidelines
for the interpretation of sequence variants because c.478T>C
meets the pathogenicity criteria PS3, PM1, PM2, and PP3 and
c.258_260del meets the pathogenicity criteria PS3 and PM4
(Richards et al., 2015).
CONCLUSION
In conclusion, our data support the pathogenicity of the
two RNASEH1 variants found in a patient with PEO
syndrome, multiple deletions, and mild mitochondrial myopathy,
phenotypic traits that are characteristic of other patients with
mutations in the same gene.
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